Oddity Tech (ODD) investor relations material

Executive summary

• Achieved record 2025 results with net revenue of $810 million, up 25% year-over-year, and adjusted EBITDA of $163 million, surpassing internal plans and prior guidance.

• Q4 2025 net revenue was $153 million, up 24% year-over-year, exceeding guidance.

• Launched third brand, METHODIQ, expanding into medical-grade telehealth, with strong early traction.

• Continued heavy investment in ODDITY Labs, technology infrastructure, and molecule discovery platform.

• Ended the year with $776 million in cash and equivalents, maintaining a strong balance sheet.

Financial highlights

• FY 2025 gross margin was 72.7%, up 30 basis points year-over-year; Q4 gross margin was 70.5%, down 220 basis points year-over-year but above guidance.

• Q4 adjusted EBITDA was $13 million (8.2% margin), above guidance but down year-over-year due to growth investments and higher media costs.

• Full-year adjusted diluted EPS was $2.21, up from $1.96 in 2024.

• Free cash flow for 2025 was $84 million; net operating cash flow was $88 million.

• Advertising costs rose 50% year-over-year, reflecting growth investments and higher acquisition costs.

Outlook and guidance

• Not issuing full-year 2026 guidance due to uncertainty around timing of user acquisition cost normalization.

• Q1 2026 sales expected to decline approximately 30% year-over-year due to increased user acquisition costs.

• Q2 2026 sales also likely to decline, with magnitude yet to be determined.

• Expect normalization of acquisition costs and business performance in H2 2026, pending successful remediation.

• Management will issue FY 2026 guidance in the coming months.